PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
OSL:PHO - Euronext Oslo - NO0010000045 - Common Stock - Currency: NOK
Overall PHO gets a fundamental rating of 5 out of 10. We evaluated PHO against 53 industry peers in the Pharmaceuticals industry. While PHO has a great health rating, there are worries on its profitability. While showing a medium growth rate, PHO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PHO had positive earnings in the past year.
In the past year PHO had a positive cash flow from operations.
PHO had negative earnings in 4 of the past 5 years.
PHO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
PHO's Return On Assets of 0.30% is on the low side compared to the rest of the industry. PHO is outperformed by 66.04% of its industry peers.
The Return On Equity of PHO (0.45%) is worse than 66.04% of its industry peers.
The Return On Invested Capital of PHO (1.79%) is worse than 66.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROIC | 1.79% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 0.40%, PHO is doing worse than 64.15% of the companies in the same industry.
With a Operating Margin value of 2.64%, PHO is not doing good in the industry: 64.15% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of PHO has declined.
PHO's Gross Margin of 93.97% is amongst the best of the industry. PHO outperforms 94.34% of its industry peers.
In the last couple of years the Gross Margin of PHO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHO is destroying value.
Compared to 1 year ago, PHO has about the same amount of shares outstanding.
PHO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHO has been reduced compared to a year ago.
2.2 Solvency
PHO has an Altman-Z score of 5.46. This indicates that PHO is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PHO (5.46) is better than 84.91% of its industry peers.
PHO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.46 |
ROIC/WACC0.21
WACC8.52%
2.3 Liquidity
A Current Ratio of 3.81 indicates that PHO has no problem at all paying its short term obligations.
PHO's Current ratio of 3.81 is amongst the best of the industry. PHO outperforms 94.34% of its industry peers.
A Quick Ratio of 3.44 indicates that PHO has no problem at all paying its short term obligations.
PHO's Quick ratio of 3.44 is amongst the best of the industry. PHO outperforms 96.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
PHO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -86.67%.
The Revenue has been growing slightly by 3.95% in the past year.
PHO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.29% yearly.
EPS 1Y (TTM)-86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
Revenue 1Y (TTM)3.95%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%6.19%
3.2 Future
PHO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 190.44% yearly.
PHO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.98% yearly.
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 3085.00, the valuation of PHO can be described as expensive.
Based on the Price/Earnings ratio, PHO is valued a bit more expensive than 71.70% of the companies in the same industry.
PHO is valuated expensively when we compare the Price/Earnings ratio to 28.05, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 30.35, which means the current valuation is very expensive for PHO.
Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than 67.92% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 37.67. PHO is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3085 | ||
| Fwd PE | 30.35 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 69.81% of the companies listed in the same industry.
PHO's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.87 | ||
| EV/EBITDA | 32.32 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHO does not grow enough to justify the current Price/Earnings ratio.
PHO's earnings are expected to grow with 190.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.44
PEG (5Y)N/A
EPS Next 2Y264.59%
EPS Next 3Y190.44%
5. Dividend
5.1 Amount
PHO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (7/28/2025, 4:06:54 PM)
61.7
+0.7 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.92%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.67B
Analysts82.5
Price Target79.05 (28.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-94.41%
Min EPS beat(2)-203.96%
Max EPS beat(2)15.13%
EPS beat(4)2
Avg EPS beat(4)-37.97%
Min EPS beat(4)-203.96%
Max EPS beat(4)47.82%
EPS beat(8)5
Avg EPS beat(8)40.12%
EPS beat(12)6
Avg EPS beat(12)-9.06%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.7%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)-2.17%
Revenue beat(4)1
Avg Revenue beat(4)-3.95%
Min Revenue beat(4)-9.78%
Max Revenue beat(4)1.4%
Revenue beat(8)3
Avg Revenue beat(8)-3.64%
Revenue beat(12)6
Avg Revenue beat(12)-2.7%
Revenue beat(16)7
Avg Revenue beat(16)-4.28%
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)-155%
EPS NQ rev (3m)-155%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)-6.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3085 | ||
| Fwd PE | 30.35 | ||
| P/S | 3.14 | ||
| P/FCF | 25.87 | ||
| P/OCF | 22.09 | ||
| P/B | 3.55 | ||
| P/tB | 7.09 | ||
| EV/EBITDA | 32.32 |
EPS(TTM)0.02
EY0.03%
EPS(NY)2.03
Fwd EY3.29%
FCF(TTM)2.38
FCFY3.86%
OCF(TTM)2.79
OCFY4.53%
SpS19.64
BVpS17.4
TBVpS8.71
PEG (NY)3.44
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROCE | 2.32% | ||
| ROIC | 1.79% | ||
| ROICexc | 3.13% | ||
| ROICexgc | 9.81% | ||
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% | ||
| FCFM | 12.14% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score5
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.09% | ||
| Cap/Sales | 2.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 175.53% | ||
| Profit Quality | 3024.79% | ||
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 5.46 |
F-Score5
WACC8.52%
ROIC/WACC0.21
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue 1Y (TTM)3.95%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%6.19%
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
EBIT growth 1Y-61.13%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year105.28%
EBIT Next 3Y59.66%
EBIT Next 5YN/A
FCF growth 1Y1030.99%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y590.65%
OCF growth 3Y47.56%
OCF growth 5Y30.02%